Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

n cancer cells, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Everolimus is being studied in multiple tumor types, including breast cancer, neuroendocrine tumors, gastric cancer, hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma (NHL), as well as tuberous sclerosis complex (TSC).

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in these cancer and tumor types. Access to everolimus for these cancer and tumor types is available through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. For more information about everolimus clinical trials, healthcare professionals can visit www.theWIDEprogram.com. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever become commercially available for these cancer and tumor types anywhere in the world.

Afinitor (everolimus) tablets important safety information

Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients. Potentially serious adverse reactions to Afinitor include non-infectious pneumonitis and infections, for which patients should be monitored carefully and treated as needed. In addition, non-infectious pneumonitis may require temporary dose reduction and/or interruption or discontinuation. Patients with systemic invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect of Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CORONA, Calif. and VIENNA, Va. ... an innovative in-home care provider that operates in ... with BeClose, a leading provider of remote caregiving technology. Alta ... new and existing client receiving homecare services. ... believe this technology is the key to providing the ...
(Date:11/21/2014)... SARASOTA, Fla. , Nov. 21, 2014   ... ) announced that the Company is scheduled to present ... San Francisco, CA on January 12-14, ... PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will ... small molecule cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. ...
(Date:11/21/2014)... 2014  Abaxis, Inc. (NasdaqGS: ABAX ), ... for the medical, research, and veterinary markets worldwide and ... markets in the United States , ... to acquire 100% of QCR & Trio Diagnostics Limited, ... organization. The transaction closed on November 17, 2014. ...
Breaking Medicine Technology:Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Abaxis Acquires UK-based Distribution Organization 2Abaxis Acquires UK-based Distribution Organization 3Abaxis Acquires UK-based Distribution Organization 4
... DUBLIN, October 18, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... the PRECiSE 3 (P3) open label extension study for ... maintenance trial for an anti-TNF in Crohn,s disease, will ... the American College of Gastroenterology (ACG), taking place in ... efficacy data from the PRECiSE 4 (P4) clinical trial ...
Cached Medicine Technology:Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 2Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 3Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 4Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 5Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 6Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 2UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 3UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 4UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 5UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 6UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 8UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 9UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 10UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 11
(Date:11/23/2014)... 2014 Locks-Magnetic.com, a notable magnetic locks ... all the new products are available at low rates ... is proud of the new emergency doors. The emergency ... customers can choose from several colors. All of the ... emergency door release is not as easy as many ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... Church, VA (PRWEB) November 23, 2014 ... TV Have in Common, **FDAnews On-Demand Webinar**, Dec. 11, ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional activities ... , Now they're looking at websites, Twitter, ... Mark the calendar for Thursday, Dec. 11, for On-Demand ...
(Date:11/23/2014)... Salt Lake City, Utah (PRWEB) November 23, 2014 ... in individual health insurance reimbursement for small businesses, ... the new book, The End of Employer-Provided Health ... employer-provided health insurance is the greatest financial risk ... greatest challenge facing U.S. employers, small and large, ...
(Date:11/22/2014)... (PRWEB) November 23, 2014 PrettyTailor ... website with a new big promotion. Customers can buy ... detailed information, customers can visit its website. , As ... apparel and occasion dresses. It mainly provides four types ... bride dresses and flower girl dresses. It also provides ...
Breaking Medicine News(10 mins):Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... , ... proceeds from its sales to facilitate a speedy recovery from one of the world’s worst ... established to help in the rebuilding of Haiti. MBMI hopes that this initiative will inspire ... ...
... blood test in office, not home tests , THURSDAY, ... proper use of a colorectal cancer screening method called the ... from the U.S. Centers for Disease Control and Prevention surveyed ... them order or perform an in-office fecal occult blood test ...
... researchers from Georgetown University,s Institute for Reproductive Health to ... by a growing number of women to help plan ... wish to become pregnant are unsuccessful because they do ... American Infertility Association. CycleBeads is a fertility management aid ...
... ... for Healthcare Conference, taking place in Houston, TX April 19, 20 and 21, 2010. ... session, "Next Practices" and Best Practices in Learning and Development at Kaiser Permanente. ... Cambridge, MA ...
... more minutes to fall asleep , THURSDAY, April 15 (HealthDay ... well if he indulges in a violent video game right before ... teens who played the popular video game "Call of Duty 4: ... who watched a documentary. , A report on the finding appears ...
... ... celebrating a one-of-a-kind event with the Grand Opening of its new location in ... author Jacqueline Wilson, will be spilling the best kept dog training secrets and ... pet services and products. Guests and their pets will enjoy gourmet foods and ...
Cached Medicine News:Health News:MBMI Steel Buildings is Saving Haiti One Building at a Time 2Health News:Many Doctors Not Using Colon Cancer Test Properly 2Health News:Getting the bead on conception 2Health News:Getting the bead on conception 3Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 2Health News:Interaction Associates to Sponsor HCI Talent Management for Health Care Conference 3Health News:Video Games Before Bed May Not Shortchange Slumber 2Health News:Video Games Before Bed May Not Shortchange Slumber 3Health News:Shi Shi Pet Boutique's Open House Happy Hour Benefiting 'Brooke's Lucky Dog Rescue' Saturday April 24, 2010 4:00pm - 8:00pm 2
Each handle is designed to fit a specific trephine size....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Each handle is designed to fit a specific trephine size....
Reusable, stainless steel trephine with handle....
Medicine Products: